These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
216 related articles for article (PubMed ID: 19185908)
1. Combined androgen blockade revisited: emerging options for the treatment of castration-resistant prostate cancer. Simmons MN; Klein EA Urology; 2009 Apr; 73(4):697-705. PubMed ID: 19185908 [No Abstract] [Full Text] [Related]
2. A re-assessment of the role of combined androgen blockade for advanced prostate cancer. Klotz L; Schellhammer P; Carroll K BJU Int; 2004 Jun; 93(9):1177-82. PubMed ID: 15180600 [No Abstract] [Full Text] [Related]
3. Chemotherapy in patients with castration-resistant prostate cancer. Meulenbeld HJ; Hamberg P; de Wit R Eur J Cancer; 2009 Sep; 45 Suppl 1():161-71. PubMed ID: 19775615 [No Abstract] [Full Text] [Related]
4. Combined castration and androgen blockade therapy in prostate cancer. Conclusions. Denis L; Mettlin C Cancer; 1990 Sep; 66(5 Suppl):1086-9. PubMed ID: 2203520 [No Abstract] [Full Text] [Related]
5. Antiandrogens in the treatment of prostate cancer. Wirth MP; Hakenberg OW; Froehner M Eur Urol; 2007 Feb; 51(2):306-13; discussion 314. PubMed ID: 17007995 [TBL] [Abstract][Full Text] [Related]
6. [Cancer of the prostate. What treatment, for which patient, in 1986?]. Boccon-Gibod L Ann Urol (Paris); 1986; 20(2):79-81. PubMed ID: 3717903 [No Abstract] [Full Text] [Related]
8. Effects of androgen suppression and radiation on prostate cancer suggest a role for angiogenesis blockade. Woodward WA; Wachsberger P; Burd R; Dicker AP Prostate Cancer Prostatic Dis; 2005; 8(2):127-32. PubMed ID: 15643450 [TBL] [Abstract][Full Text] [Related]
9. [Endocrine therapy versus observation after R0 resection in node positive prostate cancer]. Kleeberg UR Strahlenther Onkol; 2000 Jun; 176(6):293-4. PubMed ID: 10897259 [No Abstract] [Full Text] [Related]
10. Novel concepts in androgen receptor blockade. Hsieh AC; Ryan CJ Cancer J; 2008; 14(1):11-4. PubMed ID: 18303477 [TBL] [Abstract][Full Text] [Related]
12. Metastatic prostate cancer presenting as paraneoplastic pemphigus: a favourable clinical response to combined androgen blockade and conventional immunosuppressive therapy. Mignogna MD; Fortuna G; Leuci S; Adamo D; Ruoppo E Br J Dermatol; 2009 Feb; 160(2):468-70. PubMed ID: 19120335 [No Abstract] [Full Text] [Related]
13. [Clinical usefulness of chlormadinone acetate as an alternative antiandrogen therapy for prostate cancer relapse after combined androgen blockade therapy]. Ehara H; Katoh S; Nakane K; Katoh T; Takada T; Kojima K; Kamei S; Hagiwara N; Yuhara K; Takahashi Y; Fujimoto Y; Fujihiro S; Kanimoto Y; Deguchi T Hinyokika Kiyo; 2009 Apr; 55(4):199-203. PubMed ID: 19462824 [TBL] [Abstract][Full Text] [Related]
14. A combination treatment for localized prostate cancer. Mayo Clin Health Lett; 2005 Feb; 23(2):4. PubMed ID: 15732168 [No Abstract] [Full Text] [Related]
15. Novel secondary hormonal therapy in advanced prostate cancer: an update. Van Allen EM; Ryan CJ Curr Opin Urol; 2009 May; 19(3):315-21. PubMed ID: 19342958 [TBL] [Abstract][Full Text] [Related]
16. Prostate cancer (non-metastatic). Wilt T Clin Evid; 2003 Dec; (10):1023-38. PubMed ID: 15555136 [No Abstract] [Full Text] [Related]
17. Prostate cancer (non-metastatic). Wilt T Clin Evid; 2003 Jun; (9):973-85. PubMed ID: 12967402 [No Abstract] [Full Text] [Related]
18. Where is radiotherapy for stage C prostate cancer headed? Hanks GE Contemp Urol; 1994 Mar; 6(3):11-4. PubMed ID: 10146746 [No Abstract] [Full Text] [Related]